Analyst firms · UBS · EHAB
UBS EHAB price target and rating history
Enhabit Inc. (EHAB) · Health Care
UBS rates Enhabit Inc. (EHAB) Buy with a $12 price target, as of its latest action on Jan 8, 2026. It has published 3 rating actions on EHAB since December 2022, including 2 upgrades and 0 downgrades. Across 4 firms with a EHAB price target in the last 12 months, the median target is $12.90. UBS's $12 is 7% below that.
- Current rating
- Buy
- Price target
- $12
- Median target, all firms
- $12.90
- Actions on EHAB
- 3
UBS price target on EHAB
Every UBS rating on EHAB
- Jan 8, 2026
- Mar 7, 2024
- Dec 8, 2022
How other firms rate EHAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Hold | $13.80 | Mar 6, 2026 |
| Oppenheimer | Outperform | $14 | Jan 22, 2026 |
| UBS | Buy | $12 | Jan 8, 2026 |
| Truist Securities | Hold | $10.50 | Jan 7, 2026 |
Questions about UBS and EHAB
- What is UBS's price target for EHAB?
- UBS's latest stated price target for Enhabit Inc. (EHAB) is $12, from its action on Jan 8, 2026.
- What is UBS's rating on EHAB?
- UBS rates EHAB Buy, a bullish rating, as of Jan 8, 2026.
- When did UBS last change its view on EHAB?
- On Jan 8, 2026, UBS upgrades to Buy from Neutral, price target $12.
- How does UBS's EHAB target compare with other analysts?
- Across 4 firms with a EHAB price target in the last 12 months, the median target is $12.90. UBS's $12 is 7% below that.
More EHAB rating histories
All UBS ratingsEHAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.